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Abstract
Objective: Electromyography (EMG) is used routinely to diagnose neuromus-
cular dysfunction in a wide range of peripheral neuropathies, myopathies, and
neuromuscular degenerative diseases including motor neuron diseases such as
amyotrophic lateral sclerosis (ALS). Definitive neurological diagnosis may also
be indicated by the analysis of pathological neuromuscular innervation in
motor-point biopsies. Our objective in this study was to preempt motor-point
biopsy by combining live imaging with electrophysiological analysis of slow
degeneration of neuromuscular junctions (NMJs) in vivo. Methods: We com-
bined conventional needle electromyography with fiber-optic confocal endomi-
croscopy (CEM), using an integrated hand-held, 1.5-mm-diameter probe. We
utilized as a test bed, various axotomized muscles in the hind limbs of anaes-
thetized, double-homozygous thy1.2YFP16: WldS mice, which coexpress the
Wallerian-degeneration Slow (WldS) protein and yellow fluorescent protein
(YFP) in motor neurons. We also tested exogenous vital stains, including
Alexa488-a-bungarotoxin; the styryl pyridinium dye 4-Di-2-Asp; and a GFP
conjugate of botulinum toxin Type A heavy chain (GFP-HcBoNT/A). Results:
We show that an integrated EMG/CEM probe is effective in longitudinal evalu-
ation of functional and morphological changes that take place over a 7-day
period during axotomy-induced, slow neuromuscular synaptic degeneration.
EMG amplitude declined in parallel with overt degeneration of motor nerve
terminals. EMG/CEM was safe and effective when nerve terminals and motor
endplates were selectively stained with vital dyes. Interpretation: Our findings
constitute proof-of-concept, based on live imaging in an animal model, that
combining EMG/CEM may be useful as a minimally invasive precursor or alter-
native to motor-point biopsy in neurological diagnosis and for monitoring local
administration of potential therapeutics.
Introduction
Diagnosis of neuromuscular or neurodegenerative disease
is frequently based on clinical examination supplemented
by data obtained on motor unit or muscle function via
surface or needle electromyography (EMG).1–3 For
instance, diagnosis of amyotrophic lateral sclerosis (ALS)
and other motor neuron diseases is currently informed by
a combination of clinical evaluation and interpretation of
functional deficits, low-resolution imaging (X-rays and
MRI), analysis of cerebrospinal fluid, genotyping for
familial forms of the disease, and EMG.4–10 Diagnosis of
ALS and other neuromuscular diseases may also be cor-
roborated by histopathological and electrophysiological
analysis of motor-point biopsies: that is, explants of
whole muscles or muscle tissue containing intramuscular
nerve branches and neuromuscular junctions (NMJs).11–20
Subsequent treatments may be systemic but topical
administration of drugs or other treatments, including
therapeutic neurotoxins such as botulinum toxin
(BoNTx), is also indicated in some cases.21–24 Methods
that enable localization and direct visualization of NMJs
in situ may therefore facilitate analysis and interpretation
of EMG, without recourse to an invasive motor-point
ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1
biopsy, and may also improve the targeting and efficacy
of potential treatments.25
We show here, using mice, that live imaging of intra-
muscular axons and NMJs, with a hand-held confocal en-
domicroscope (confocal endomicroscopy, CEM) can
readily be combined with EMG recording, enabling
simultaneous morphological and physiological appraisal
of neuromuscular synaptic pathology in situ. We took
advantage of two useful phenotypes in this study: trans-
genic expression of yellow fluorescent protein (YFP) in
motor neurons, driven by the thy1.2 promoter26–28; and
slow synaptic degeneration induced by axotomy in the
WldS (Wallerian-degeneration Slow) natural mouse
mutant.27,29–32 We have shown previously that synaptic
degeneration can be observed and monitored effectively
in vivo using CEM27,33 in double homozygotes of these
two lines (thy1.2YFP16: WldS); also in the thy1.2YFP16:
hSOD1G93A transgenic mouse model of ALS; and in an
ENU mutant with defective axon regeneration.27,34 Our
extended goals in this study were therefore first, to com-
bine CEM with EMG using an integrated probe; second,
to use the integrated probe to extend the time course and
detail of longitudinal description of neuromuscular syn-
aptic degeneration in vivo; and third to make progressive
steps toward identifying potential fluorochromes that
could label NMJs with high contrast, by localized infusion
rather than transgenic expression of fluorescent proteins.
We also present data supporting the safety of the method
from the standpoints of mechanical damage, phototoxic-
ity, or neuromuscular paralysis.
Together, our findings constitute proof-of-concept that
combining simultaneous EMG recording and CEM imag-
ing may be a safe approach for observing the form and
function of NMJs in situ. The data suggest that this
approach could be further developed and translated to
the routine study of neuromuscular synaptic structure
and function, either in healthy human subjects; or as a
precursor or alternative, in some conditions, to motor-
point biopsy for evaluation of neuromuscular synaptic
pathology; and/or as a method for accurate delivery and
monitoring of effective treatments, in cases of neurode-
generative or neuromuscular disease.35
Methods
Animals
All animals (mice and rats) were housed in cages of six or
fewer, and maintained with Local Ethical Committee
approval and with the approval under UK Home Office
Project and Personal Licences, in accordance with the Uni-
ted Kingdom Animals (Scientific procedures) Act, 1986.
Mice of the thy1.2YFP16:C57Bl6 and thy1.2YFP16:WldS
strains were obtained from in-house breeding colonies
(University of Edinburgh) generated initially using the
thy1.2YFP16 line obtained originally from Jackson Labo-
ratories (Bar Harbor, ME) and C57Bl6 and the innocuous
mutant WldS line obtained originally from Harlan-Olac
(Bicester, UK). Due to the age dependency of the WldS
phenotype27,32,36 only animals aged 5–10 weeks were
included in this study. At the end of the experiments, ani-
mals were sacrificed by cervical dislocation. In some
experiments, Sprague–Dawley rats weighing 100–300 g
were used instead of mice.
Sciatic nerve section
Animals were prepared for surgery with a subcutaneous
injection of Vetergesic (0.05 mg kg1 Alstoe-Sogeval UK
Ltd.). They were then anaesthetized by inhalation of iso-
flurane and oxygen (2–5%, 0.4–1 L/min; Merial Animal
Health, Harlow, UK). The area surrounding the sciatic
notch was shaved and wiped with a sterilizing solution. A
small incision was made, and then blunt dissection was
used to expose the sciatic nerve. A small section (~2 mm)
of the nerve was removed. The wound was then closed
with 7/0 silk suture (Ethicon, Livingston, UK).
Repeated visualization of nerve terminals
and axons27
A Cellvizio confocal endomicroscope (Mauna Kea Tech-
nologies, Paris, France) fitted with an S-1500 1.5-mm-
diameter Proflex optical fiber probe was used to monitor
axonal and synaptic degeneration in anaesthetized mice.
Utilization of thy1.2YFP16 transgenic mice26,27 permitted
us to observe axonal and neuromuscular synaptic degen-
eration within the same, reanaesthetized animals at several
time points. A small incision was made in the hind limb,
exposing the tibial nerve, and NMJs of muscles in the
vicinity, including flexor digitorum longus and gastrocne-
mius. The probe was micromanipulated by hand, placing
its tip in direct contact with the exposed muscle surface.
Fluorescence excitation was provided by the 488 nm
wavelength from the inbuilt diode laser. Fluorescence
emission (500–650 nm) was collected through the same
optical fibers at 12 video frames per second. Images were
acquired and processed using ImageCell (Mauna Kea
Technologies), Adobe Photoshop (USA), or ImageJ
software (downloadable from http://imagej.nih.gov/ij/),
running on Apple Mac G5 or Powerbook computers. To
study the degeneration of nerve terminals following sciatic
nerve lesion, thy1.2YFP16: WldS mice (N = 32) and
thy1.2YFP16: C57Bl6 (N = 9 mice) were reanaesthetized
and NMJs visualized up to four times over a 7-day period
post axotomy. The amount of innervation in these images
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was estimated from the proportion of axon terminal
branches that supplied a discernible motor axon terminal.
To test whether CEM imaging might itself produce
phototoxic damage, we imaged NMJ clusters in three
mice with intact sciatic nerves, repeatedly over a 7-day
period. In addition, to monitor the acute effects of
intense illumination, we monitored recovery from photo-
bleaching of YFP. Four thy1.2YFP16:WldS mice were
anaesthetized and tibial nerve exposed. Maximal illumina-
tion was applied for 3–5 min. The CEM probe was held
in place with a micromanipulator, and the nerve then
briefly imaged at reduced laser power, at 10-min intervals
over the following 60 min.
EMG recording
Compound muscle action potentials (CMAP) were
recorded using a monopolar EMG needle (50 9 0.45
mm; Ambu, St. Ives, UK) attached to the CEM probe via
a small length of silicone rubber tubing (3.0 mm external
diameter, 1.5 mm internal diameter; Portex-Smiths Medi-
cal, Ashford, UK Ltd.) and inserted into muscles along-
side the CEM probe. A reference electrode was positioned
in the foot and a ground electrode was inserted rectally.
The sciatic nerve was exposed via a small incision at the
thigh level, and placed on a bipolar hook electrode. Stim-
ulation pulses of 0.2-msec duration and up to 10 V in
amplitude were delivered by a Digitimer DS2 stimulator
(Digitimer, Welwyn Garden City, UK) via a Powerlab
(ADInstruments Oxford, UK), driven by Scope software
running on Apple Mac Powerbook. CMAP amplitude and
latency were also measured using this software. Animals
were culled either by overdose of anesthetic or by cervical
dislocation after the final recording. In some cases, the
tibial nerve and/or NMJs in the contralateral hind limb
were imaged and EMG recorded at this stage.
Vital staining
Acetylcholine receptors (AChR) in postsynaptic mem-
branes were stained using a fluorescent Alexa488 conju-
gate of a-bungarotoxin (Alexa488-a-BTX).37,38 Lumbrical
muscles were dissected from the hind feet of C57Bl6 mice
(N = 3) and incubated with Alexa488-a-BTX (Invitrogen-
Life Technologies, Paisley, UK, UK; 5 lg/mL) in mamma-
lian physiological saline (MPS), containing 120 mmol/L
NaCl, 5 mmol/L KCl, 2 mmol/L CaCl2, 1 mmol/L MgCl2,
0.4 mmol/L NaH2PO4, 23.8 mmol/L NaHCO3, 5.6 mmol/
L D-glucose. The muscles were then washed twice with
MPS for 10 min and then fixed in 4% paraformaldehyde
(PFA) for 20 min. After washing twice again with MPS
for 10 min, the muscle was mounted in Mowiol (Calbio-
chem, Merck Millipore Watford, UK) and imaged using a
Nikon Eclipse/Bio-Rad Nikon: Kingston-upon-Thames,
UK; BioRad: Hemel Hempstead, UK. Radiance confocal
microscope using a 409 oil immersion lens. For live
imaging in vivo, Alexa488-a-BTX (5 lg/mL) was injected
into the interstitial spaces of the inner leg of six mice,
using an Inoject EMG needle (30 9 0.36 mm; Ambu)
attached to the Cellvizio probe (see Fig. 4). The solution
was left on the muscle for 20 min before washing away
the excess with saline. CEM and/or EMG were performed
before and after application of the solution.
In two muscles, motor nerve terminals were labeled
using the styryl pyridinium dye 4-Di-2-Asp (4-(4-dieth-
ylaminostyryl)-1-methylpyridinium iodide, Sigma Aldrich,
20 lmol/L in MPS Gillingham, UK). This cationic mito-
chondrial dye was previously used extensively to reimage
mouse motor nerve terminals in vivo, until it was super-
seded by transgenic expression of YFP.26,39–41 The muscles
were pinned in Sylgard-lined Petri dishes and bathed in
dye solution for 15 min, followed by a 5-min wash in
MPS. The muscles were then mounted in Mowiol and
images were captured into OpenLab software (Perkin
Elmer, Coventry, UK) on an Apple Mac G5 computer via
a Hamamatsu Orca-ER camera. Hamamatsu Photonics
UK Ltd., Welwyn Garden City, UK Further image pro-
cessing was performed in Adobe Photoshop. For live
imaging by CEM, a higher concentration of 4-Di-2-Asp
(40 lmol/L) was injected into intramuscular spaces of
eight mice, as described above for Alexa488-a-BTX. Lower
concentrations produced weaker fluorescence that was
difficult to detect with CEM. Motor nerve terminals were
imaged in all mice and EMG recorded in three of the
mice for up to 60 min. Nerve terminal and postsynaptic
endplate imaging using 4-Di-2-asp and Alexa488-a-BTX,
respectively, were repeated in three rats.
Botulinum toxin labeling
GFP-labeled botulinum toxin Type A heavy chain
(HcBoNTx/A) has been previously shown to label nerve
terminals both after direct muscle application and
repeated in vivo injections.42 We explored a similar
approach, with the aim of developing a nontoxic stain
that could be used to image nerve terminals in vivo using
CEM. The C-terminal binding domain (HC) of type A
botulinum neurotoxin was expressed as a GFP fusion
protein from the plasmid pET29-GFP-HC/A (a kind gift
of Professor J. Oliver Dolly, Dublin), in RossettaTM 2
(DE3)pLysS (NEB). Bacterial cultures were grown in LB
media at 37°C, 220 RMP to an OD580 0.7, at which point
isopropyl b-D-1-thiogalactopyranoside (IPTG) was added
to 0.5 mmol/L, the temperature reduced to 18–20°C, and
the incubation continued for a further 16–18 h. Bacteria
were harvested by centrifugation at 7500g for 10 min at
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4°C. The bacterial pellet was washed once and then resus-
pended in a solution of 10 mmol/L TrisHCl pH 8.5,
10 mmol/L imidazol, 300 mmol/L NaCl, and CompleteTM
– EDTA protease inhibitors (Roche Burgess Hill, UK)
(binding buffer), at 1 mL per 10 mL starting culture. This
cell suspension was subject to two freeze/thaw cycles and
then sonicated on ice to reduce viscosity (Soniprep 150;
MSE/Sanyo London, UK). The cell lysate was then centri-
fuged at 7500g for 20 min at 4°C, and the supernatant
loaded on to a 1 mL His-TALONTM gravity flow column
(Clontech Saint-Germain-en-Lay, France). The column
was washed with 109 column volumes of binding buffer,
and eluted in 10 mmol/L TrisHCl pH 8.5, 150 mmol/L
imidazol, and CompleteTM–EDTA protease inhibitors. GFP
fluorescence was used to identify fractions containing
recombinant protein, which were pooled and extensively
dialyzed against phosphate-buffered saline (pH 7.5).
In an initial test of the GFP-tagged HcBoNTx/A prod-
uct, we dissected lumbrical muscle fans (deep lumbrical
muscles 1–4 attached to their common calcaneus tendon
of origin but detached from their insertions) and triangu-
laris sterni muscles from five C57 Bl6 mice, pinned them
in a Sylgard-lined Petri dish and bathed them in GFP-
HcBoNTx (400 lg/mL) in MPS for 90 min. Preparations
were then washed twice for 10 min in normal MPS.
AChR at motor endplates were then counterstained with
rhodamine–bungarotoxin (TRITC-a-BTX; 5 lg/mL in
MPS for 15 min), and then washed twice for 10 min in
MPS. The muscles were then mounted in Mowiol and
imaged with conventional confocal microscopy (as
above). For live imaging, 10 mice were injected subcuta-
neously in the inner leg with 3 lL of 0.5 or 1 mg/mL
GFP-HcBoNTx/A in MPS using a Hamilton syringe
Bonaduz, Switzerland. After an hour, the mice were anes-
thetized and the muscles imaged by CEM as described
above.
Measurement of synaptic transmission
Wild-type mice (C57/Bl6, N = 9 mice) were used to test
whether 4-Di-2-Asp (10–20 lmol/L, nine muscles) or
GFP-HcBoNTx/A (400 lg/mL, two muscles from one
mouse) impair neuromuscular transmission. The hind
limbs of animals sacrificed by cervical dislocation were
removed and the skin stripped. The limbs were pinned
on to a Sylgard-lined Petri dish, and immersed in fresh
oxygenated MPS equilibrated with 95% oxygen 5% CO2.
Flexor digitorum brevis (FDB) nerve-muscle preparations
were dissected and used for electrophysiological analy-
sis.32,43 The muscles were pinned in a Sylgard-lined
recording chamber. The tibial nerve supply was stimu-
lated using a glass suction electrode connected to a Digi-
timer DS2 stimulator, controlled by a Digitimer D4030
programmer. Electrode glass (1.5 mm o.d. 9 0.86 mm
i.d., Harvard Apparatus, Edenbridge, UK) was pulled on
a Sutter Flaming/Brown micropipette puller (P87;) and
filled with 4mol/L potassium acetate. Microelectrode tip
resistances were around 30–70 MO. Muscle fibers
were impaled and EPPs recorded using an Axoclamp 2B
amplifier (Axon Instruments Molecular Devices,
Wokingham, UK). The percentage of innervated fibers
was estimated from impalements of 30 randomly selected
fibers, by scoring the number of fibers giving an evoked
response upon supramaximal stimulation of the tibial
nerve. A CED micro1401 interface transferred data to a
computer (Dell Bracknell, UK), and EPPs were analyzed
using WinWCP software (Strathclyde Electrophysiological
Software, University of Strathclyde, UK). For quantal
analysis, trains of 30 EPPs were recorded from each
muscle fiber at 0.5–1 Hz. WinWCP software was used to
analyze quantal content using the variance method.43,44
The Mclachlan–Martin correction factor ‘f’ for non-lin-
ear summation45 was set to 0.3 and the reversal potential
was assumed to be 10 mV. Spontaneous MEPP activity
was recorded for approximately 100 s for each fiber
using Spike-2 software (Cambridge Electronic Design,
Cambridge UK). Recordings were analyzed using Mini-
analysis (Synaptosoft, Atlanta GA), with auto detection
of MEPPs. As resting membrane potential (RMP) affects
MEPP amplitude, recordings were only taken from fibers
with RMP more negative than 60 mV.
Statistical analysis
Data presented in the text and figures are mean  SEM
unless stated otherwise. GraphPad prism (GraphPad Soft-
ware Inc. San Diego, CA) was used for statistical analysis.
Normality was assumed and significance (P < 0.05) was
evaluated using either unpaired t-tests or one-way ANO-
VA with Bonferroni post hoc tests, where appropriate.
Results
Longitudinal study of neuromuscular
synaptic degeneration
We coupled a monopolar EMG needle to a CEM S-1500
probe and used this to monitor NMJ form, function, and
degeneration in vivo (Fig. 1A; Video S1). High-contrast,
selective fluorescence of intramuscular axons and motor
terminals in thy1.2YFP16 transgenic mice was readily
detected using this probe.
Intense, acute illumination of YFP-labeled axons via
the 488-nm laser in the CEM control unit did not appear
to impair axonal structure or function. In four mice, we
used maximum laser power to illuminate the exposed
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tibial nerve for 5 min, which produced photobleaching of
the illuminated region (Fig. 1B). Reexamination over the
following 60 min with reduced laser power showed that
fluorescence recovered along a moving front, presumably
by a combination of spontaneous recovery of fluores-
cence46 and by effective transport of fluorescent protein
from adjacent, unilluminated regions through the illumi-
nated region47 (Fig. 1C–E).
We also examined the effect of illumination on the
morphology of tibial nerve axons and NMJs, and on
EMG responses to tibial nerve stimulation at multiple
time points in the same animals (Fig. 1F–I). In three
mice, there was no discernible fragmentation or any other
evidence of degeneration of tibial nerve axons (Fig. 1F
and G) or NMJs (Fig. 1H and I). EMG responses were
also unimpaired (Fig. 1J): that is, the mean difference in
the peak amplitude of the compound muscle action
potential (CMAP) between measurements on the same
region of the same mice, 7 days apart was 0.19  0.02
mV (n = 3; P > 0.05, paired t-test). Thus, neither axonal
nor NMJ structure, nor nerve conduction and neuromus-
cular transmission were significantly impaired by repeated
visualization of the same neuromuscular synapses, 7 days
apart.
Next, we obtained CMAPs and CEM images from
thy1.2YFP16: WldS mice immediately then up to 7 days
after axotomy by section of the sciatic nerve (Fig. 2). As
expected,27,32 at 2 days post axotomy, there were no overt
Figure 1. Simultaneous EMG recording and live CEM imaging does not damage axons or NMJ. (A) standard monopolar EMG needle electrode
secured to a 1.5-mm-diameter Proflex fiber-optic probe. (B–E) CEM images of motor axons in the tibial nerve in a thy1.2YFP16:WldS mouse
before (0 min) and 5 min after full-power laser illumination, bleaching YFP fluorescence in the vicinity of the CEM probe tip, with subsequent
recovery over the following 20–60 min. The moving front of recovery suggests that this was at least partly by axonal transport of YFP into the
bleached region. (F and G) CEM images of left-side tibial nerve axons in the same reanaesthetized mouse, imaged 7 days apart. (H and I) CEM
images of the same cluster of NMJs imaged 7 days apart; insets show EMG responses recorded in the same vicinity. (J) Peak amplitudes of EMG
responses measured in the vicinity where images of motor nerve terminals were obtained 7 days apart. The differences were not significant
(n = 3 mice; P > 0.05; paired t-test). Overall, these data suggest that CEM caused no axonal or presynaptic terminal damage and the peak
amplitude of the evoked EMG response remained within the normal range. EMG, Electromyography; NMJ, neuromuscular junctions; CEM,
confocal endomicroscopy; YFP, yellow fluorescent protein.
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signs of deterioration of motor nerve terminal structure
and muscles contracted vigorously in response to stimula-
tion (Fig. 2A and B; Video S2). However, CMAP were
discernibly reduced in amplitude (Fig. 2B and E), consis-
tent with our previous observations of demise in physio-
logical response before frank denervation of muscle
fibers.27,31,32 EMG recording and revisualization of NMJs
5–7 days post axotomy (Fig. 2C and D) showed progres-
sive deterioration of CMAP amplitude (Fig. 2E) and an
increase in nerve-excitation threshold, measured by the
stimulus intensity required to evoke a CMAP response
(Fig. 2F). CMAP amplitude decreased from its initial
value, 18.53  0.67 mV (n = 32 muscles), to 11.61 
3.48 mV at 48 h (n = 4), 9.37  2.66 mV at 3 days
(n = 5), 4.39  1.21 mV at 5 days (n = 7), and 5.65 
2.00 mV at 7 days (n = 7; F = 24.76; df = 54; P <
0.0001, ANOVA, Bonferroni post hoc t = 7.01,
P < 0.001). The threshold for excitation was unchanged
up to 5 days post axotomy (control: 0.52  0.09 V,
n = 13 muscles; 2 days axotomy: 0.37  0.09 V, n = 3;
3 days axotomy: 0.45  0.12 V, n = 4; 5 days axotomy:
0.85  0.20 V, n = 7; P > 0.05 one-way ANOVA). At
7 days post axotomy, the threshold was significantly
increased compared to controls (2.44  1.09 V n = 5,
F = 3.89; df = 31; P < 0.02, one-way ANOVA; Bonferroni
post hoc t = 3.68, P < 0.05; Fig. 2F).
Morphological indicators of progressive muscle fiber
denervation matched the deterioration of CMAPs mea-
sured physiologically. Still frames from CEM video
recordings obtained at each time point were selected and
Figure 2. Combining EMG and CEM gives complementary data on slow neuromuscular synaptic degeneration. (A–D) CEM Images (above) and
EMG recordings of CMAPs (below) from thy1.2YFP16: WldS mice at sequential times after sciatic nerve section, indicated in days after sciatic
nerve section. The WldS gene protects axons and nerve terminals from rapid Wallerian degeneration, so that most nerve terminals are still intact
and the EMG appears normal or only slightly reduced for at least 2 days post axotomy (Panel B is a still frame from Video S2). By 5 days, several
motor nerve terminals had degenerated (arrows) and there was a significant reduction in amplitude of the evoked EMG. By 6–7 days, most NMJ
had degenerated and the EMG response was substantively reduced. (E) decline in EMG response; and (F) increase in stimulus intensity threshold
required to evoke an EMG response with time after axotomy in thy1.2YFP16: WldS mice. (G) Quantification of loss of motor axon terminals from
NMJ, over the same 2- to 7-day period. Numbers embedded in each column are the numbers of muscles studied in that group. Asterisks indicate
significance at P < 0.05 (ANOVA and post hoc Bonferroni tests). Scale bars in A–D, 50 lm. EMG, Electromyography; NMJ, neuromuscular
junctions; CEM, confocal endomicroscopy; YFP, yellow fluorescent protein; CMAPs, compound muscle action potentials.
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the percentage of endplates (n = 20–30 sampled in each
muscle) showing clearly visible nerve terminals or intra-
muscular axon stumps were scored in order to provide a
morphological estimate of nerve terminal degeneration
(Fig. 2G). In control muscles, 100  0% intramuscular
axons had a visible nerve terminal (n = 3 muscles). At
2 days, 98.21  1.04% of axon branches were tipped by
an arborized axon terminal (n = 4), compared with
86.67  6.67% at 3 days (n = 3) and 66.91  8.04% at
day 5 post axotomy (n = 7). By 7 days, the reduction in
the number of visible nerve terminals compared to con-
trols was substantial (22.46  6.55%, n = 6, P < 0.001,
t = 7.11, one-way ANOVA with Bonferroni post hoc test,
F = 21.25, total df, 22). Thus, the amount of presynaptic
degeneration estimated morphologically using CEM was
similar to estimates made more directly by measuring
motor endplate occupancy using conventional fluores-
cence or confocal microscopy.27,32
We also recorded EMG responses from axotomized
YFP16 Bl6 animals (wild type for WldS) at 0, 24, and
48 h (Fig. S1). As expected,27,32,48,49 the normal and rapid
rate of Wallerian degeneration in these mice caused the
amplitudes of recorded CMAPs to decrease precipitously:
from 17.58  0.80 mV (n = 14 muscles) at the time of
nerve section; to 0.86  0.53 mV, (n = 5) at 24 h and
0.59  0.59 mV at 48 h (n = 4; F = 124.0, df = 22;
P < 0.001, one-way ANOVA).
Together, the data suggest that CEM is not inherently
toxic or disruptive to the structural and functional
integrity of axons or motor nerve terminals; and, when
combined with EMG, this live imaging method can pro-
vide complementary morphological and physiological data
in longitudinal studies of slow, progressive synaptic
degeneration.
Exogenous vital staining of NMJs
Translating CEM/EMG recording into a clinical context
will require labeling of NMJs with high-contrast fluoro-
chromes, without recourse to transgenic expression of
fluorescent proteins. We first tested the feasibility of this
in six mice by local infusion of Alexa488-a-BTX, to label
postsynaptic acetylcholine receptors (Fig. 3). As expected
and indicated by simultaneous EMG recording, labeling
AChR with this irreversible toxic ligand blocked synaptic
transmission within 20 min of application, both in vivo
and in vitro (Fig. 3B; Video S3). Bright, high-contrast
fluorescent endplates were subsequently discernible in
Figure 3. NMJ can be visualized using CEM after local injection of fluorochromes. (A) Combined CEM/EMG and hypodermic needle probe (1 mL
syringe) used to exogenously administer fluorochromes in vivo. (B) EMG recordings following instillation of Alexa488-a-BTX. As expected, the
labeled toxin produced progressive and eventually complete neuromuscular block. (C) CEM image of fluorescent motor endplates after local
infusion of Alexa488-a-BTX. (D) Standard confocal microscopic image of NMJ labeled by infusion with Alexa488-a-BTX for comparison. (E)
Intramuscular axons in a thy1.2YFP16: WldS mouse 5 days after axotomy. Axons were pseudocolored yellow. (F) The same group of intramuscular
axons reimaged after infusion of Alexa488-a-BTX. Endplates were masked and then pseudocolored green, to differentiate their denervated state,
denuded of overlying motor nerve terminals. Compare, for example, with Figures 1H and 2A. EMG, electromyography; NMJ, neuromuscular
junctions; CEM, confocal endomicroscopy.
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both mice (Fig. 3C and D) and rats (data not shown).
Alexa488-a-BTX was also applied to muscles in
thy1.2YFP16: WldS mice, 5 days after sciatic nerve section.
The fluorescence intensity of Alexa488-a-BTX-labeled
endplates was similar to that of YFP fluorescence of the
axons. Alexa488-a-BTX staining also confirmed that sev-
eral axons had lost their motor nerve terminals (Fig. 3E
and F; compare with Fig. 2).
Having established that a fluorescent ligand could be
locally administered to NMJs and provide sufficient bright-
ness and contrast to allow motor endplates to be visualized
readily by CEM, we next asked whether high-contrast
labeling of motor nerve terminals could be obtained using
other exogenous fluorescent dyes. We explored this possi-
bility initially using the cationic styryl pyridinium dye
4-Di-2-Asp, which has previously been used to label NMJs
in vivo.39,50 This dye labeled nerve terminals when injected
in vivo at a concentration of 40 lmol/L both in mice
(Fig. 4A; Video S4) and rats (Fig. 4B, Video S5).
4-Di-2-Asp has been reported to have no overtly toxic
effects on NMJs and only weak anticholinergic activity at
acute concentrations of 15–50 lmol/L, based on its effect
on spontaneous miniature endplate potential amplitudes
and efferent activity in cell types other than muscle.51–53
There was no overt effect of 4-Di-2-Asp on CMAPs
recorded with the adjoined EMG electrode (17.32 
0.69 mV at 0 min (n = 3 muscles), 17.68  0.17 mV at
60 min (n = 3), t-test, P = 0.32, t = 0.506, df = 4;
Figure 4. Motor nerve terminals can be identified using CEM following infusion of 4-Di-2-Asp. (A and B) Images of fluorescent motor nerve
terminals following local infusion of 4-Di-2-Asp in mouse (A) and rat (B) muscle. The contrast is less than with transgenic expression of YFP and
axons are unlabeled but motor nerve terminals are discernible (arrows). (C and D) EMG recordings of averaged CMAP (14 and 20 sweeps,
respectively) obtained before local administration of 4-Di-2-Asp and 60 min later. There was no discernible effect on functional response. (E and
F) Intracellular recordings of evoked EPPs; and (G and H) spontaneous MEPPs before and 60 min after adding 4-Di-2-Asp (20 lmol/L) to isolated
FDB muscles. (I) Amplitude of EPPs decreased significantly over time (r2 = 0.43, F = 15.98, P < 0.0001). (J) Spontaneous MEPPs also decreased in
amplitude (r2 = 0.29, F = 7.57, P < 0.02). (K) Quantal content of EPPs also declined, and (L) spontaneous MEPP frequency increased progressively
over the period of incubation in the dye (summary data in I–L are based on recordings from three to five muscles at each time point. *P < 0.05,
ANOVA, post hoc Bonferroni test). None of these effects was evident when the 4-Di-2-Asp concentration was reduced to 10 lmol/L (see Fig. S2).
CMAPs, compound muscle action potentials; EMG, electromyography; NMJ, neuromuscular junctions; CEM, confocal endomicroscopy; FDB, flexor
digitorum brevis.
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Fig. 4C and D). To reevaluate any potential toxicity, how-
ever, we measured both spontaneous and evoked neuro-
muscular transmission in isolated FDB nerve-muscle
preparations bathed in 4-Di-2-Asp (10–20 lmol/L) in
normal MPS. At a concentration of 10 lmol/L, we
observed no significant effect on MEPP amplitude or fre-
quency, nor were the amplitudes of EPPs significantly
attenuated (Fig. S2). However, when the concentration
of 4-Di-2-Asp was increased to 20 lmol/L, endplate
potential peak amplitude slowly and progressively
declined (initially: 25.77  1.21 mV, n = 4 muscles; at
10 min: 24.43  1.24 mV, n = 5; at 20 min: 22.20 
2.28 mV, n = 5; at 30 min: 21.91  2.10 mV, n = 5;
and at 60 min: 15.6  2.48 mV, n = 4; linear regres-
sion r2 = 0.43, F = 15.98, P < 0.0001; Fig. 4E, F, and I).
MEPP amplitude was also reduced (0 min: 1.01 
0.17 mV, n = 3 muscles; 10 min: 0.84  0.10 mV, n = 5;
20 min: 0.67  0.11 mV, n = 5; 30 min: 0.86  0.22
mV, n = 4; 60 min: 0.42  0.08 mV, n = 4; linear regres-
sion: r2 = 0.29, F = 7.57, P < 0.02; Fig. 4G–H and J).
Quantal analysis of the EPPs showed no compelling
evidence for any substantive decrease in transmitter
release and the slight, nonsignificant downward trend
could have been due to the loss of signal:noise ratio of
uniquantal responses, as MEPP amplitude declined and
the smallest responses became buried in the recording
noise (0 min: m = 48.09  5.80 quanta, n = 4 muscles;
10 min: m = 48.66  8.52, n = 5; 20 min: 38.42  4.82,
n = 5; 30 min: 33.88  4.91, n = 5; 60 min: 32.17 
4.62, n = 4; P > 0.05 one-way ANOVA, Fig. 4K). How-
ever, there was evidence of a presynaptic effect based on a
progressive increase in spontaneous transmitter release
(Fig. 4H and L). MEPP frequency at 0 mins was 0.33 
0.02 s1 (n = 3 muscles), and was not significantly differ-
ent to MEPP frequency at 10 min (0.34  0.06 s1,
n = 5) or 20 min (0.47  0.06 s1, n = 5). The MEPP
frequency became more variable between fibers at 30 mins
(1.80  1.08 MEPPs s1, n = 4). By 60 min, mean
MEPP frequency was significantly increased (3.96  0.97
MEPPs s1, n = 4; P < 0.05 ANOVA).
Taken together, this analysis is consistent with a weak
anticholinergic effect of 4-Di-2-Asp, reported previously,
at concentrations above 20 lmol/L.52 Thus, although not
overtly toxic, low concentrations of 4-Di-2-Asp may cause
mild impairment of neuromuscular transmission in vivo,
due to reduced MEPP amplitude and an increase in spon-
taneous MEPP frequency; but, based on the persistence of
CMAPs in EMG recordings, this appears not to have been
sufficient to impair overall neuromuscular function. Fur-
ther evaluation of these anticholinergic effects may be
worthwhile, however, in order to establish whether 4-Di-
2-Asp might be a suitable fluorescent marker for vital
staining of NMJs in humans.
Finally, we evaluated the potential utility of fluorescent
conjugates of inactivated botulinum toxin type A. The
native toxin blocks synaptic transmission via enzymic
cleavage of the synaptic protein SNAP-25, which is essen-
tial for vesicular exocytosis and transmitter release.53–55
BoNTx/A binds to receptors on motor nerve terminal
membranes via its heavy chain and removing the light
chain renders the protein nontoxic.56,57 We therefore
tested a GFP-tagged heavy chain construct of BoNTx/A
(GFP-HcBoNTx/A)42 for toxicity and efficacy of staining
and visualization of motor nerve terminals (see Methods).
Conventional confocal microscopy and microelectrode
recordings of EPPs revealed high-contrast staining of
motor nerve terminals without blocking neuromuscular
transmission (Fig. 5). Bath application of GFP-HcBoNTx/
A (1 mg/mL) to two FDB nerve-muscle preparations
(n = 1 mouse) for up to 1 h had no effect on EPP ampli-
tude (20.40  7.78 mV [SD] compared with 18.51 
4.22 mV; n = 30 muscle fibers in each case; P > 0.05
t-test) or quantal content (m = 49.16  26.05 compared
with 63.68  23.07; Fig. 6B and C; P > 0.05 t-test).
Unfortunately, fluorescence intensity of motor termi-
nals exogenously labeled with GFP-HcBoNTx/A was
much weaker than the endogenous fluorescence of motor
terminals in thy1.2YFP16 mice. To compare the fluores-
cence with that of YFP, we imaged nerve terminals in tri-
angularis sterni (TS) muscles dissected from thy1.2YFP16
mice and non-YFP mice, labeled with GFP-HcBoNTx/A.
We used identical settings of laser power, photomultiplier
gain, and offset and scanning rate. The images in Figure 6
show that fluorescence was about 10 times weaker in
terminals labeled with GFP-HcBoNTx/A compared with
that of the YFP transgenics (Fig. 6). GFP-HcBoNTx/A
(1 mg/mL) in vivo produced barely discernible nerve
terminal staining (Fig. 6B and C; Video S6). The fluores-
cence was therefore too weak and its detection too
unreliable for us to undertake a longitudinal study using
this form of labeling of motor nerve terminals using
GFP-HcBoNTx/A.
Discussion
We have demonstrated here that combining live imaging
and electromyographic recording provides complementary
information about the structure and function of motor
units and the integrity of their neuromuscular connec-
tions, under conditions where both may be compromised:
specifically, during progressive neuromuscular synaptic
degeneration. This was technically achievable for three
main reasons: first, the size and mechanical flexibility of
the endomicroscopy probe; second, utilization of trans-
genic mice that strongly express YFP in motor neurons,
yielding high-contrast, selective vital staining of axons
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and motor nerve terminals; and third, utilization of a
natural mutation that delays synaptic degeneration. These
advantages also define the principle limitations that must
be confronted before extending and translating the
method to clinical applications.
Probe limitations
Although fitted with a flexible, slender (1.5 mm diameter)
probe and with an acquisition video frame rate (12 fps)
that permits smooth real-time visualization, our CEM/
EMG recording approach is limited, optically, by light
sensitivity and a nominal working distance of zero: that
is, maximum acuity is obtained at the probe’s interface.
The principle advantage of this is that high-contrast
images of axons and motor nerve terminals are obtainable
by gliding the probe face over a muscle surface in the
region of the NMJs. One disadvantage is that, in a clinical
context, neuromuscular pathology may lie much deeper
and, therefore, more invasive penetration of the probe tip
may be necessary in order to visualize neuromuscular
defects. A further risk is that locating NMJs, especially
deep within muscle, might require multiple penetrations
with the probe. The number and accuracy of penetrations
required would most likely be improved upon with expe-
rience, perhaps supplemented by preliminary surface and/
or single-fiber needle EMG recording (SFEMG),1,4,58,59
thus identifying the most likely locations of NMJs in the
regions of interest.
Fluorochromes
As in our previous study, we obtained very good contrast
and morphological delineation, within the specification of
Figure 5. Motor nerve terminals imaged after labeling with GFP conjugates of HcBoNTx/A. (A) Conventional confocal microscopic images of
motor nerve terminals (green, left) labeled with GFP-HcBoNTx/A, and motor endplates labeled with TRITC-a-bungarotoxin (red); together with a
merged image showing complete coherence of labeled pre- and postsynaptic structures. (B) Intracellular recordings of evoked EPPs showed no
evidence of impairment in synaptic physiology after labeling with GFP-HcBoNTx/A; and (C and D) there was no significant change in either peak
amplitude or quantal content of EPPs 30–60 min after administration of the fluorochrome (mean  SD, n = 2 muscles from one mouse, 30 fibers
sampled in each).
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a 5-lm spatial resolution, using transgenic expression of
YFP in motor neurons.26,27 Finding safe fluorochromes
that readily stain motor axons and their endings with high-
contrast and high quantum yield, thus visualizing a similar
degree of structural detail, remains perhaps the most signif-
icant challenge facing extension of CEM to diagnostic neu-
rology. However, we have made progress toward this goal
in this study. Postsynaptic staining of acetylcholine recep-
tors by injection and local infusion of a fluorescent conju-
gate of a-BTX yielded images of comparable intensity and
contrast to presynaptic labeling with YFP. But the concen-
trations used to ensure such visualization blocked
neuromuscular transmission, and the affinity of a-BTX for
its receptor, were such that dissociation would take several
days after its administration in vivo60–62 and meanwhile,
such binding may also destabilize AChR and provoke inter-
nalization of the BTX-bound complexes.63–65 Moreover,
although endplate morphology is in register with, and thus
reflects, presynaptic terminal structure in healthy muscle,
postsynaptic staining gives no direct clue regarding the
integrity of presynaptic terminals in disease or following
nerve damage (with or without reinnervation).
We also obtained discernible staining of motor nerve
terminals using the vital dye 4-Di-2-Asp, which – prior to
Figure 6. Fluorescence of motor nerve terminals labeled with GFP-tagged HcBoNTx/A was weak. (A) Identical setting of laser power and
photomultiplier gain and black level in a conventional confocal microscope were used to image motor terminals in thy1.2YFP16 mouse muscle
(left column) and wild-type muscles labeled by infusion of GFP-HcBoNTx/A (middle column). The fluorescence intensity of simultaneous TRITC-a-
BTX labeling is shown as a positive control for microscope setting (middle row) and merged images (bottom row). Increasing the power of the
488-nm argon laser rendered terminals more discernible (right column) but the brightness was still less than that of transgenic expression of YFP.
(B) Low power image of motor nerve terminals (arrows) in a muscle labeled by infusion of GFP-tagged HcBoNTx/A. The background intensity is
high due to the maximum setting of the laser power. (C) Digital zoom on of one motor nerve terminal visualized using CEM in a muscle labeled
by GFP-tagged HcBoNTx/A. Background subtraction and contrast stretching were used to enhance the differentiation of the labeled terminal
against background.
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the advent of transgenic expression of fluorescent proteins
in motor neurons using the thy1.2 promoter26–28 – was a
fluorochrome of choice for vital staining of motor nerve
terminals in longitudinal studies of NMJ morphology in
vivo.39,40,52 We also obtained images using a GFP conju-
gate of the botulinum toxin heavy chain. However, the
intensity of fluorescence of motor nerve terminals labeled
by injection and infusion in vivo with this fluorochrome
was substantively less than with 4-Di-2-Asp and consider-
ably less than the fluorescence of transgenically expressed
YFP (see Fig. 6). Fluorescent conjugates of botulinum
toxin heavy chain remain attractive as candidate neuro-
muscular fluorochromes, since the active form (contain-
ing the enzymically active light chain) is already licensed
for clinical and cosmetic applications. However, the data
from this study suggest that GFP-HcBoNTx/A does not
have a sufficient photon yield for detection by CEM, at
least in our hands. Perhaps by increasing the photon yield
of fluorescent ligands bound to the BoNTx/A heavy
chain, or to its receptor in nerve terminal membranes,
will enable this attractive molecular target to be exploited
more effectively and to achieve its full potential for appli-
cations to CEM imaging. Quantum yield of fluorescence
could be increased by uniting HcBoNTx/A with other
conjugates.66 Alternatively, targeting fluorescent ligands to
other receptors in presynaptic terminals could improve
the contrast and intensity of the motor nerve terminal
fluorescence. Seeking highly fluorescent molecular probes
that compete for the botulinum toxin heavy chain recep-
tor may be a fruitful strategy.67 A promising alternative
approach may be to utilize aptamer screening for empiri-
cal selection of suitable fluorochromes. This approach has
proved successful in identifying fluorescent compounds
that effectively stain axons in peripheral nerve but unfor-
tunately not, thus far, at NMJs.68.
Monitoring axonal and synaptic
degeneration in vivo
Homozygous WldS mutant mice display a remarkable,
covert phenotype: protection from Wallerian degenera-
tion that delays axonal and synaptic degeneration by an
order of magnitude compared with wild-type mice.27,36,69
Thus, while Wallerian degeneration is complete within
1–3 days of axotomy in wild-type mice, almost all of the
intramuscular axons and motor nerve terminals remain
wholly intact for about 3 days after section of the sciatic
nerve and only then degenerate, in a progressive fashion,
via a process of asynchronous retraction of synaptic bou-
tons from motor endplates.31,32,69 This phenotype, which
evidently arises via substitution of the stable enzymic
activity of the chimeric WldS protein for unstable axonal
Nmnat2,70–72 is of considerable practical utility for devel-
opment of methods such as those described in this
study.27 We also showed in a previous report that CEM
enables longitudinal study and visualization of progressive
synaptic degeneration in the SOD1 mouse model of ALS
and in a mouse model of disease with slow axon regener-
ation.27 Thus, utilization of WldS mice and other mouse
models has enabled us to identify and evaluate asynchro-
nous synaptic degeneration in both investigator-triggered
and spontaneous synaptic degeneration. Additional exper-
imental validation is necessary to establish further the
optical limitations of the method: for instance, whether
collateral and motor nerve terminal sprouting can be
visualized, following either chronic paralysis or partial
denervation.38,53,55
Translational potential of EMG/CEM
Electromyography (EMG) is widely used as a diagnostic
tool for neuromuscular disorders, including motor neu-
ron diseases such as ALS.2,73–75 Clinical applications of
CEM have, thus far, included investigation of the GI
tract,76 urinary tract,77 respiratory tract78, and cardiovas-
cular system.79 The present findings lay a foundation for
extending CEM to neurological investigation and using it,
in association with conventional EMG recording, for
diagnosis and monitoring the efficacy of potential treat-
ments of neuromuscular disease.
What are the likely benefits of combining EMG and
CEM in a clinical context? First, direct visualization of
neuromuscular synaptic morphology in situ could pre-
empt or complement histopathological investigation by
motor-point biopsy. Motor-point biopsies have been
most frequently used in diagnosis and characterization of
several forms of myasthenia.15–17,19,20,80,81 Thus, CEM
may be a viable alternative to motor-point biopsy in these
conditions. Second, a combination of CEM and EMG
may facilitate earlier diagnosis of neurodegenerative axon-
opathies such as ALS.35,82–84 EMG analysis allows earlier
diagnosis and shows abnormalities in nonsymptomatic
regions in ALS patients.2,85,86 However, most of our
knowledge regarding NMJ pathology in ALS derives from
limited data obtained via motor-point biopsy12–14 or
postmortem tissue.82,83 Although it has been argued that
neuromuscular synaptic degeneration is an early sign of
disease in animal models,41,87–89 the evidence for this in
human ALS is less compelling and indirect.41,82,83,86 An
efficient imaging method for defining, detecting, and
monitoring disease onset and progression at NMJs at dif-
ferent stages may facilitate diagnosis of different forms of
the disease and establish the role of the NMJ in disease
onset and progression.
Finally, there is intense contemporary interest in possi-
bilities for transplanting differentiated cells derived
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from human embryonic stem (ES) cells or inducible
pluripotent stem (iPS) cells, either as vehicles for delivery
of therapeutic cargoes or for functional regeneration of
axons and NMJs.90–94 Since it is possible to express fluo-
rescent protein in these cells,90,92,93,95–97 CEM/EMG may
facilitate the localized delivery of cell-based therapeutics,
contributing to development of effective, novel treatments
for diseases like ALS.
Conclusion
In summary, CEM is minimally invasive, and it can be
applied without causing overt mechanical or photochemi-
cal damage to motor axons and their terminals. It pro-
vides novel morphological data at 5-lm resolution, via a
probe that is smaller in diameter than most needle-biopsy
probes, and can be utilized at the same time as EMG
recording, via integration of standard needle electrodes.
CEM, in combination with EMG recording, may preempt,
or constitute an attractive alternative to, motor-point
biopsy for visualization of neuromuscular synaptic integ-
rity. CEM may also be used to monitor the localized
administration of potential therapeutics. Thus, adjoining
EMG recording with CEM-based live, real-time imaging
of NMJs in humans would constitute a powerful and
refined approach to research, clinical diagnosis, follow-up
investigations, and monitoring the efficacy of treatment
of neuromuscular disease.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Axotomized wild-type motor terminals degen-
erate rapidly. (A and B) CEM Images of intramuscular
axons in wild-type (thy1.2YFP16: C57Bl6) mice 24 h and
48 h, respectively, after sciatic nerve section. (C) EMG
recording 24 h after nerve section in the vicinity of intra-
muscular axons like those shown in A, showing records
in response to progressively increasing stimulus intensity,
from 1 to 30 V. The large spike is a stimulus artifact due
to stimulation at over 30 V intensity applied to the tibial
nerve: there was no evoked CMAP. (D) Peak EMG ampli-
tude in control (n = 14 muscles), and 1 day (n = 5) and
2 days (n = 4) after axotomy. Responses were lost within
24–48 h. Almost all motor nerve terminals degenerated
within 24 h in these mice, with concomitant loss of
evoked neuromuscular responses.
Figure S2. Low concentrations of 4-Di-2-Asp (10 lmol/L)
have no effect on neuromuscular transmission. (A) EPPs
and (B) MEPPs recorded after 60-min incubation. There
was no significant linear regression over 1 h of incubation
in: (C) EPP amplitude, (D) MEPP amplitude, (E) quantal
content, or (F) MEPP frequency. Each data point in C–F
shows the mean  SEM and the calculated best fit linear
regression. n = 4 muscles, three muscle fibers sampled in
each muscle at each time point. The slopes were not signifi-
cantly different (P > 0.05, linear regression in all four cases.)
Video S1. CEM of intramuscular axons and motor nerve
terminals in a control thy1.2YFP16: WldS mouse. The
Proflex probe was glided over the surface of the muscle
while capturing images in real time at 12 fps, while the
sciatic nerve was supramaximally stimulated. Twitching of
the muscle is discernible.
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Video S2. CEM of motor nerve terminals imaged in real
time at 12 fps during sciatic nerve stimulation;
thy1.2YFP16: WldS mouse, 2 days after sciatic nerve sec-
tion. Note the intermittent twitching of the muscle pro-
duced by stimulation of the distal, tibial nerve stump.
Video S3. CEM of motor endplates imaged in real time
at 12 fps, following instillation of Alexa488-a-bungaro-
toxin. The fluorescence is due to postsynaptic labeling of
AChR.
Video S4. CEM of motor nerve terminals imaged in real
time at 12 fps following instillation of 4-Di-2-Asp to label
motor nerve terminals in a nontransgenic (C57Bl6)
mouse.
Video S5. CEM of motor nerve terminals imaged in real
time at 12 fps following instillation of 4-Di-2-Asp to label
motor nerve terminals in a Sprague–Dawley rat.
Video S6. CEM of motor nerve terminals imaged in real
time at 12 fps following instillation GFP-HcBoNTx/A, to
label motor nerve terminals in a nontransgenic (C57Bl6)
mouse.
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